0
New
New
2022
General Anesthesia Drugs Market

General Anesthesia Drugs Market by TYPE OF DRUGS (Propofol, Sevoflurane, Desflurane, Others), by ROUTE OF ADMNISTRATION (Intravenous, Inhalation), by SURGERY TYPE (Knee and hip replacements, Heart surgeries, Cancer surgery, General surgery), by END USER (Hospital, Ambulatory surgical centers): Global Opportunity Analysis and Industry Forecast, 2021-2031

A05262
Pages: 284
May 2022 | 2771 Views
Author(s) : Linu Dash, Tanjeem Shaikh , Onkar Sumant
Tables: 176
Charts: 63
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the General Anesthesia Drugs Market

Request Now !

General Anesthesia Drugs Market Statistics - 2031

The global general anesthesia drugs market size was valued at $5.4 billion in 2021, and is projected to reach $7.7 billion by 2031, growing at a CAGR of 3.5% from 2022 to 2031. The general anesthesia drug is the induction and maintenance of state of unconsciousness with the absence of pain sensation. It is basically induced state of unconsciousness accompanied by partial or complete loss of protective reflexes. It is administered in combination with medication through intravenous or inhalation route. Propofol, etiomide, ketamine are some intravenous general anesthetic drugs and sevoflurane desflurane are inhalation anesthesia drugs. General anesthesia is used in various cardiac surgeries, hip and knee replacement surgeries, cancer surgeries, and gastro-intestinal surgeries.

The COVID-19 outbreak is anticipated to have a negative impact on growth of the general anesthesia drug market. The pandemic has stressed healthcare systems in the world and cause decline in the demand of general anesthesia drug due to canceled or postpone of elected surgeries. According to the report share by British Journal of Surgery in May 2020, it was reported that, approximately 28.4 million elected surgeries estimated to be canceled in 2020 over the globe.

The growth of the global general anesthesia drugs market share is majorly driven by increase in prevalence of chronic disease such as cancer, cardiovascular disease, osteoarthritis; rise in demand for inhalation anesthesia; increase in funding from private & government organizations for development of pharmaceutical manufacturing segments; and rise in R&D activities for formulation of general anesthesia drug. In addition, according to World Health Organization, in 2022, it was reported that cardiovascular disease is the most common cause of death, across the globe. Patients with coronary heart disease, heart failure, atrial fibrillation, are more prone to open heart surgery procedure. The open heart surgery is conducted under general anesthesia. This factor propels the growth of the market.

General Anesthesia Drugs Market, General Anesthesia Drugs Market size, General Anesthesia Drugs Market share, General Anesthesia Drugs Market trends, General Anesthesia Drugs Market growth, General Anesthesia Drugs Market analysis, General Anesthesia Drugs Market forecast, General Anesthesia Drugs Market opportunity

Get more information on this report : Request Sample Pages

 

Furthermore, increase in number of approval for general anesthesia drug drives growth of the market. For instance, in September 2020, U.S Food and Drug Administration (FDA) announced the approval for propofol injectable emulsion. It is a general intravenous anesthesia and sedation drugs, used before surgical procedure.  In addition, increase in number of surgical procedure is anticipated to contribute toward growth of the general anesthesia drugs market. According to the Canadian Joint Replacement Registry (CJRR), it was reported that more than 75,000 knee replacement and 63,000 hip replacement surgeries were performed in Canada from 2019 to 2020.  Moreover, increase in prevalence of geriatric population, who are more susceptible to chronic diseases, due to hormonal change and aging effect propel the growth of the market. According to the Interactive cardiovascular and thoracic surgery, in April 2022, it was reported that around 227,442 population above 70 years undergo cardiovascular procedure.

Furthermore, R&D activities in the pharmaceutical industry to formulate novel general anesthesia drug is expected to provide remunerative opportunities for expansion of the global general anesthesia drugs market during the general anesthesia drugs market forecast period. Moreover, presence of key manufacturing companies to manufacture and distribute general anesthesia drugs products and rise in expenditure on healthcare products propel the growth of the general anesthesia drugs market. For instance, in April 2020, Hikma pharmaceutical Plc, a pharmaceutical company, announced the launch of vecuronium Bromide for Injection, which is a new general anesthesia drug. Initiatives taken by government and private organizations to develop pharmaceutical industry propel the growth of the market. However, the side effect associated with general surgery such as nausea, vomiting, and allergy reaction, is expected to restrict the general anesthesia drugs market growth during the forecast period.

Global General Anesthesia Drug Segmentation

The general anesthesia drugs market is segmented on the basis of type of drug, route of administration, surgery type, end user and region. By type of drug, the market is categorized into propofol, sevoflurane, desflurane and other. Further the others are categorized into ketamine, thiopental, methohexital, etomidate, isoflurane, fospropofol. By route of administration, the market is divided into intravenous and inhalation. By surgery, the market is classified into knee and hip replacements, heart surgeries, cancer surgery, general surgery. By end user, the market is divided into hospital and ambulatory surgical centers. 

General Anesthesia Drugs Market
By Type Of Drugs

Your browser does not support the canvas element.

Others segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

Depending on type of drug, the others segment dominated the general anesthesia drugs market in 2021, and this trend is expected to continue during the forecast period, owing to increase in number of approval for general anesthesia drugs. However, the sevoflurane segment is expected to witness considerable growth during the forecast period, owing to increase in demand for inhalation anesthesia, and rise in number of key players for manufacturing of sevoflurane inhalation anesthesia drug.

General Anesthesia Drugs Market
By Route Of Admnistration

Your browser does not support the canvas element.

Inhalation segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By route of administration, the inhalation segment was the major contributor in 2021, and is expected to maintain its lead during the forecast period, owing to rise in number of diagnostic procedure, and increase in government support regarding the use of inhalation anesthesia. However, the intravenous anesthesia segment is expected to witness considerable growth during the forecast period, owing to increase in number of surgical procedure, such as open heart surgery.

General Anesthesia Drugs Market
By Surgery Type

Your browser does not support the canvas element.

Knee and hip replacements segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

On the basis of surgery type, the knee and hip replacements segment dominated the general anesthesia drugs market in 2021, and this trend is expected to continue during the forecast period, owing to increase in prevalence of osteoarthritis, rise in number of arthroplasty procedure, and increase in accident and sport related knee and hip injury. However, the heart surgery segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of cardiovascular disease and rise in number of open heart surgery procedure.

General Anesthesia Drugs Market
By End User

Your browser does not support the canvas element.

Hospital segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

On the basis of end user, the hospital segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to rise in number of hospitals, and rise in expenditure by government to improve healthcare industry. However, the ambulatory segment is expected to witness considerable growth during the forecast period, due to increase in shift of patient from inpatient to outpatient surgical procedure.

North America garnered a major share in the general anesthesia drugs market size in 2021, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of chronic disease, increase in number of approval for general anesthesia drug, presence of general anesthesia drugs industry, and development in R&D activities in healthcare sector in the region. However, Asia-Pacific is expected to register highest CAGR of 4.2% from 2022 to 2031, owing to increase in prevalence of cardiovascular disease, rise in number of surgical procedure, and growth in health care expenditures.

The key players operating in the global general anesthesia drugs market include AbbVie, AstraZeneca, Avet Pharmaceuticals Inc. B. Braun Melsungen, Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, PAION AG, Par Pharmaceutical, Pfizer

General Anesthesia Drugs Market
By Region

2031
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2021 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the general anesthesia drugs market analysis from 2021 to 2031 to identify the prevailing general anesthesia drugs market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the general anesthesia drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global general anesthesia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments & Key Market Players

Segments Sub-segments
By TYPE OF DRUGS
  • Propofol
  • Sevoflurane
  • Desflurane
  • Others

By ROUTE OF ADMNISTRATION
  • Intravenous
  • Inhalation

By SURGERY TYPE
  • Knee and hip replacements
  • Heart surgeries
  • Cancer surgery
  • General surgery

By END USER
  • Hospital
  • Ambulatory surgical centers

By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players
  • B. Braun Melsungen
  • Baxter International Inc.
  • Fresenius SE and Co. KGaA
  • Hikma Pharmaceuticals plc
  • Paion AG
  • Pfizer Inc.
  • Abbott Laboratories
  • Abbvie Inc
  • AstraZeneca plc
  • Avet Pharmaceuticals Inc
 

Loading Table Of Content...


 
 

General anesthesia is a combination of drugs which causes controllable unconsciousness. General anesthesia is used during surgery to avoid the stimulus of pain. The factors which drive the growth of the general anesthesia drug market include increase in number of surgical procedures such as cardiac surgeries, neuro surgeries, orthopedic surgeries and others.  However, the factor which restraints the growth of the general anesthesia market is risk associated with anesthetic drugs such as allergic reaction, nausea, and vomiting. Advancement in R&D activities in general anesthesia in pharmaceutical and biotechnology sector and rise in funding from government or non-government organizations to provide surgical resources, propel the growth of the market.

Further, North America is expected to witness highest growth, in terms of revenue, owing to increase in number of approval for general anesthesia drug, and development in R&D activities in healthcare sector.

Asia-Pacific was the second largest contributor to the market in 2021, and is expected to register the fastest CAGR during the forecast period, owing to increase in prevalence of cardiovascular disease, rise in number of surgical procedures, and growth in healthcare expenditures.

Flash Sale
PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of general anesthesia drugs market is $5,400.5 million in 2021.

A. The forecast period in the report is from 2022 to 2031

A. The market value of general anesthesia drugs Market in 2022 was $5,671 million

A. The base year for the report is 2021.

A. Yes, general anesthesia drugs companies are profiled in the report

A. The top companies that hold the market share in general anesthesia drugs market are AbbVie, AstraZeneca, Avet Pharmaceuticals Inc. B. Braun Melsungen, Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, PAION AG, Par Pharmaceutical, Pfizer

A. The key trends in the general anesthesia drugs market are increase in prevalence of chronic disease such as cancer, cardiovascular disease, osteoarthritis; rise in demand for inhalation anesthesia; increase in funding from private & government organizations for development of pharmaceutical manufacturing segments; and rise in R&D activities for formulation of general anesthesia drug.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
General Anesthesia Drugs Market

Start reading instantly.
This Report and over 13,000+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $4,904
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,483
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,995  $8,796
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers